First, as you'll hear from Raj, the final results from our ongoing Phase 3 PRESERVE 2 trial of trilaciclib in the metastatic setting are expected in the third quarter of this year. Given our statistical boundaries, if our trial is successful in generating results similar to that of our Phase 2 trial, they would be among the most important data generated in the first-line metastatic setting in both PDL-1 positive and negative tumors to date. Beyond that, the use of antibody drug conjugates, or ADCs, is appropriately becoming commonplace in the second line and later TNBC treatment settings in addition to other tumor types. We have shown promising benefits thus far in our ongoing Phase 2 trial when trilaciclib is combined with a TROP2 ADC, including improvements in tolerability and more recently, in initial overall survival.

We expect updated results from that trial midyear. With these and other recent results, we believe that continued clinical success in these trials could position G1 for category leadership across the spectrum of TNBC, in addition to our work in extensive stage small cell lung cancer. Now on today's call, Andrew will cover our recent commercial results, Raj will provide an update on our clinical pipeline, including our progress toward final results with our Phase 3 RESERVE 2 trial. John will then discuss the financial results for the quarter as well as our 2024 guidance. Finally, I'll be back for some concluding comments. With that, I'll turn the call over to Andrew.

Andrew Perry: Thank you, Jack. I'm glad to be with you today to provide an update on our fourth quarter 2023 sales performance and the significant progress we've made in our commercial execution over recent months, having navigated a period of slower growth during the national platinum chemotherapy shortage last year. Our goal in Q4 was to restore the momentum we have built early in the year, which has been interrupted by supply disruptions of carboplatin and cisplatin during Q2 and Q3. We were able to achieve this goal and to continue to demonstrate a broader platform of deeply adopting customer organizations. Beginning with sales results, we ended the quarter with 19% overall vial volume growth compared with Q3 2023. All 3 of our sales regions generated double-digit volume growth in the fourth quarter.

Focusing on the top 100 customer organizations, which represent around half the volume opportunity in the market, our growth was higher at 24% in the segment, and we added 2 new top 100 customers during Q4, meaning 75 of the top 100 of order COSELA launched today. The quarter, our efforts to grow in top 100s were supported by our new strategic accounts team were reflected with our latest real-world evidence data and are focused on creating systematic growth in our largest customers. And as a result, top 100 customers composed 58% of our total volume in the quarter. Community clinics and hospitals grew over 20% during Q4 and represented just over 80% of sales with the remainder being in academic centers. Our fastest-growing segment during the quarter was in customers covered by volume-based contract agreements.

Contracted customers grew 28% during the quarter and made up around 1/3 of our overall volume. We continue to see a broader base of adoption with 55 new accounts and almost 30 customers ordering 100 or more vials in Q4. Our estimate of COSELA patient share continues to grow, and although claims data for Q4 are not fully available, we estimate patient share of over 13% in the first-line market, demonstrating that there remains significant opportunity for growth. 97% of our volume in the quarter was in commercial supply with 3% provided through our patient assistance program. Our payer mix remains stable with the majority covered by Medicare and third-party payer reimbursement has remained strong. Moving into Q1 2024. We have embedded our new strategic accounts capabilities.

We continue to pursue new contract customer opportunities, and we've already seen our highest month ever for both volume and ex-factory sales in January, giving us confidence of continued growth going forward. I'll now pass the call over to Raj.

Raj Malik: Thanks, Andrew, and good morning, everyone. I'll start with a reminder of recent progress that our Phase 3 PRESERVE 2 reserve II trial in metastatic triple-negative breast cancer. Earlier this month, we announced that the independent data monitoring committee for the trial reviewed data from the interim analysis of overall survival and recommended that the trial continue to the final analysis, which would be conducted on the intent to treat or ITT population. Importantly, the DMC did not express any concerns with the trial. And as a reminder, G1 remains blinded to all data. We continue to be confident in the ability of trilaciclib to achieve a positive outcome for a variety of reasons. First, there is a greater likelihood of achieving a positive outcome at a final analysis at an interim because there are a larger number of events and a higher alpha allocation at the final analysis.

This results in the ability to detect a larger critical hazard ratio at the final analysis compared to the interim. We discussed on the last call that the critical hazard ratio was 0.61 at the interim. And the final analysis, we'll be able to pick up a larger hazard ratio of 0.67. And of course, second, the strength of the data that precedes this trial provides additional confidence. We frequently described the Phase 2 trial in which we saw statistically significant improvements in median overall survival in patients receiving trilaciclib prior to gemcitabine carboplatin compared to those receiving chemotherapy alone. Importantly, the capital Kaplan-Meier survival curves of trial participants receiving trilaciclib, plus gemcitabine carboplatin continue to separate over time compared to participants receiving placebo prior to their chemotherapy, particularly for patients with PD-L1 negative tumors.

The curve separation didn't occur until approximately 15 months. This is particularly relevant as the enrollment period for PRESERVE 2 from June 2021 until October 2022, and the interim analysis in February 2024 was conducted approximately 15 months after the last patient was enrolled. Therefore, the additional months of follow-up between the interim and final analysis could be important for the curves to continue to meaningfully separate. Equally compelling with the results that we presented in December last year at the San Antonio Breast Cancer Symposium regarding subsequent anticancer therapy use among patients that participated in the Phase 2 TNBC trial. Participants who receive trilaciclib with gemcitabine carboplatin and then receive subsequent anticancer therapy after trilaciclib discontinuation exhibited clinically meaningful improvements in overall survival with median of 32.7 months versus 12.8 months.

These results were statistically significant with a p-value of 0.001. Further, median overall survival for patients who received trilaciclib was 14 months from the time they started their first subsequent therapy compared to 5.8 months for patients who did not receive prior trilaciclib. The p-value for this analysis was also 0.001. These results show that trilaciclib can provide benefits during the administration with chemotherapy in the short term, and additional benefits after trilaciclib discontinuation by improving long-term immune surveillance. Given that pembrolizumab achieved a hazard ratio of 0.89 in the ITT population in the KEYNOTE-355 trial, achieving our boundary hazard ratio of 0.67 would mark the biggest improvement in overall survival seen in first-line metastatic triple-negative breast cancer to-date.

We look forward to the final results, which are estimated to be in the third quarter of this year. Regarding our Phase 2 trial of trilaciclib in combination with the TROP2 ADC sacituzumab govitecan. In January, we described promising initial efficacy results including meaningful improvements in median overall survival among patients receiving trilaciclib compared to historical results for the ADC alone. We expect to provide updated overall survival results midyear. Assuming the updated results remain strong, we anticipate continued partnership interest in developing trilaciclib with TROP2 ADCs that are in various stages of clinical development in TNBC and beyond. Additional clinical trials are ongoing, along with tracking real-world data to evaluate where the trilaciclib may also improve survival in extensive stage small cell lung cancer.

The potential overall survival benefit is demonstrated would supplement the already known trilaciclib benefits of myeloprotection and reductions in hospitalizations and associated costs. These ongoing survival studies and analyses in small cell lung cancer include the post-marketing study of trilaciclib prior to topotecan in approximately 300 patients. The real-world evidence we continue to generate, the most recent cut of which was presented in October at the ASCO Quality Care Symposium and a Phase 2 investigator-initiated trial at UNC Lineberger in combination with lurbinectedin, which according to the study investigator continues to look promising from the perspective of both mono protection and tumor responses. However, our near-term clinical focus over the next 6 months to remain on advancing the science in triple-negative breast cancer as we deliver the TNBC ADC Phase 2 results midyear and the Phase 3 final results in the third quarter.

With that, I'll turn the call over to John for the financial results.

John Umstead: Thanks, Raj, and good morning, everyone. As Will mentioned, full financial results for the fourth quarter and full year 2023 are available in this morning's press release and will be in the 10-K, which we expect to file at the market close. Net sales of COSELA grew 29% in the fourth quarter of 2023 to $13.9 million compared to 19% quarterly vial volume growth. This disparity is largely related to the timing of the sales. As mentioned on our November call, we recognized revenue upon delivery to distributors. We experienced an increase in patient vial demand towards the end of the third quarter of 2023, which was recognized as revenue in the fourth quarter in addition to that, which we recognized due to strong quarter-over-quarter growth.

Our total revenue for the fourth quarter of 2023 grew 45% over the fourth quarter of 2022 to $14.9 million comprised of the $13.9 million I just described in net COSELA revenue and $1 million in license revenue. This compares favorably to the $10.3 million in total revenue, including $8.9 million in product revenue in the fourth quarter of 2022. Total revenues for the full year 2023 were $82.5 million, including a net revenue of $46.3 million and license revenue of $36.2 million. For the full year 2022, total revenues were $51.3 million, including net product revenue of $31.3 million. Cost of goods sold for the fourth quarter of 2023 was $1.3 million compared to $1 million for the same period in 2022. Cost of goods sold for the full year 2023 was $7.2 million compared to $3.7 million for the prior year.

As we guided in November, our operating expenses of $122 million in 2023 were 35% lower than the $187.5 million in OpEx in 2022. Research and development expenses for the fourth quarter of 2023 were $7.4 million compared to $16.6 million for the same period in 2022. The decrease was primarily due to lower clinical program costs. R&D expenses for the full year 2023 were $43.7 million compared to $83.3 million for 2022. Our selling, general and administrative expenses for the fourth quarter of 2023 were $15.2 million compared to $23.6 million for the fourth quarter of 2022. The decrease in SG&A expenses was primarily due to decreases in personnel costs and medical affairs and further optimization of our commercialization activities. SG&A expenses for the full year 2023 were $71.1 million compared to $100.4 million for the prior year.

Regarding our cash position, we ended the fourth quarter with cash, cash equivalents and marketable securities of $82.2 million compared to $145.1 million as of December 31, 2022. Finally, regarding revenue and cash runway guidance for the full year 2024. As Jack mentioned, we expect net COSELA revenue to be between $60 million and $70 million for 2024. There is no change to our 2024 gross to net expense percentage estimates. We expect the 2024 year-end cash, cash equivalents and marketable securities balance of between $50 million to $60 million. Additionally, we will continue to look for ways to optimize our cost structure in the near term with targeted headcount reductions outside of the commercial organization and identifying other potential efficiency improvements where appropriate.

And based on the foregoing, we expect that our cash runway will take us into 2025. With that, I'll turn the call back over to Jack for some closing comments. Jack?

Jack Bailey: Thank you John, Raj, Andrew and Will. I also want to recognize the cancer community, we are thankful for the opportunity to be part of your journey. We are encouraged by the feedback we received daily from physicians who rely on COSELA to reduce the chemotherapy-related myelosuppressive side effects in their patients with extensive stage small cell lung cancer and by the demand trajectory in Q4 2023 and the beginning of Q1 2024. And while we have a strong commercial team driving COSELA penetration and demand and a clear path to profitability in this first indication, our focus is also on generating the clinical results required for TNBC category leadership. To that end, as you've heard today, we have important updated survival results from our Phase 2 study in combination with the TROP2 ADC expected midyear and final results from our ongoing Phase 3 trial in first-line metastatic triple-negative cancer expected in the third quarter of 2024.

Thank you for your time this morning. We will speak again in this format on the first quarter of 2024 call in May and see many of you at the spring investor meetings. With that, I'll turn it over to Q&A. Operator, would you please remind our listeners, how to ask question.

See also 15 States Where You’re Most Likely To Get In A Car Accident and 18 Most Tax-Friendly States to Retire in 2024.

To continue reading the Q&A session, please click here.